middle.news

Neuren’s DAYBUE Royalties Hit Record A$65M as 2026 Sales Set to Surge

11:42am on Thursday 26th of February, 2026 AEDT Pharmaceuticals
Read Story

Neuren’s DAYBUE Royalties Hit Record A$65M as 2026 Sales Set to Surge

11:42am on Thursday 26th of February, 2026 AEDT
Key Points
  • 2025 DAYBUE net sales reached US$391 million, up 12% year-on-year
  • Neuren’s 2025 royalty income rose 15% to A$65 million
  • Q4 2025 DAYBUE shipments served a record 1,070 patients
  • 2026 sales guidance of US$460–490 million implies royalties of A$70–77 million
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about NEUREN PHARMACEUTICALS (ASX:NEU)
OPEN ARTICLE